Inhibrx Biosciences Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqGS:INBX Recent Insider Transactions by Companies or Individuals
Date	Value	Name	Entity	Shares	Max Price
20 Nov 24	BuyUS$1,523,620	John Kayyem	Individual	107,186	US$14.23
03 Oct 24	BuyUS$100,005	Kristiina Vuori	Individual	6,667	US$15.00
16 Sep 24	BuyUS$629,117	Mark Lappe	Individual	40,000	US$17.13
11 Sep 24	BuyUS$99,992	Kristiina Vuori	Individual	6,636	US$15.07
10 Sep 24	BuyUS$671,150	Mark Lappe	Individual	44,000	US$15.29
03 Sep 24	BuyUS$596,763	Mark Lappe	Individual	40,000	US$16.31
29 Aug 24	BuyUS$99,960	Kristiina Vuori	Individual	7,140	US$14.00
28 Aug 24	BuyUS$139,800	Kimberly Manhard	Individual	10,000	US$13.98
23 Aug 24	BuyUS$1,037,328	Douglas Forsyth	Individual	75,000	US$14.07
21 Aug 24	BuyUS$518,282	Mark Lappe	Individual	40,000	US$12.97
05 Jun 24	BuyUS$997,024	John Kayyem	Individual	57,549	US$17.89
04 Jun 24	BuyUS$4,927,580	John Kayyem	Individual	286,786	US$18.24

Insider Trading Volume

Insider Buying: INBX insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of INBX?
Owner Type	Number of Shares	Ownership Percentage
VC/PE Firms	1,064,026	7.35%
Public Companies	1,157,926	8%
General Public	1,497,351	10.3%
Hedge Funds	1,787,705	12.3%
Individual Insiders	2,843,354	19.6%
Institutions	6,125,542	42.3%

Dilution of Shares: INBX only recently listed within the past 12 months

Top Shareholders

Top 25 shareholders own 80.7% of the company

Ownership	Name	Shares	Current Value	Change %	Portfolio %
12.4%	Viking Global Investors LP	1,787,705	US$26.8m	0%	0.09%
8%	Sanofi	1,157,926	US$17.3m	0%	no data
7.94%	John Kayyem	1,149,046	US$17.2m	5.05%	no data
7.35%	Perceptive Advisors LLC	1,064,026	US$15.9m	0%	0.38%
6.39%	Mark Lappe	925,413	US$13.9m	21.5%	no data
4.95%	BlackRock, Inc.	717,153	US$10.7m	4.99%	no data
3.8%	Walleye Capital LLC	549,999	US$8.2m	15.8%	0.06%
3.7%	Sofinnova Investment, Inc.	536,068	US$8.0m	15.7%	0.71%
3.66%	The Vanguard Group, Inc.	530,058	US$7.9m	10.9%	no data
3.55%	Brendan Eckelman	513,888	US$7.7m	0%	no data
2.55%	Slotnik Capital, LLC	369,354	US$5.5m	8.12%	2.88%
2%	Millennium Management LLC	289,361	US$4.3m	-4.56%	no data
1.74%	Geode Capital Management, LLC	251,219	US$3.8m	19.5%	no data
1.55%	Douglas Forsyth	224,564	US$3.4m	50.2%	no data
1.44%	Morgan Stanley, Investment Banking and Brokerage Investments	208,919	US$3.1m	-11.3%	no data
1.38%	Caption Management, LLC	199,998	US$3.0m	0%	0.31%
1.15%	Kennedy Capital Management LLC	166,072	US$2.5m	0.67%	0.05%
1.11%	State Street Global Advisors, Inc.	160,179	US$2.4m	7.8%	no data
1.08%	ArrowMark Colorado Holdings, LLC	157,047	US$2.4m	3.21%	0.03%
1%	Schonfeld Strategic Advisors LLC	144,178	US$2.2m	89.8%	0.02%
0.94%	PFM Health Sciences, LP	135,546	US$2.0m	0%	0.13%
0.85%	HighTower Advisors, LLC	122,500	US$1.8m	13.9%	no data
0.78%	Northern Trust Global Investments	113,009	US$1.7m	52.6%	no data
0.76%	Qube Research & Technologies Ltd	109,941	US$1.6m	-22.3%	no data
0.69%	Susquehanna International Group, LLP, Asset Management Arm	99,369	US$1.5m	-22.1%	no data

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/01/10 01:49
End of Day Share Price	2025/01/10 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Inhibrx Biosciences, Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution